<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Frutiger-UltraBlack,Bold" color="#4e67ad"/>
	<fontspec id="font1" size="9" family="Frutiger-UltraBlack,Bold" color="#007682"/>
	<fontspec id="font2" size="9" family="Courier" color="#007682"/>
	<fontspec id="font3" size="9" family="Frutiger-Light" color="#000000"/>
	<fontspec id="font4" size="9" family="Arial" color="#000000"/>
	<fontspec id="font5" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font6" size="24" family="Frutiger-UltraBlack,Bold" color="#000000"/>
	<fontspec id="font7" size="11" family="Helvetica-Black,Bold" color="#ffffff"/>
	<fontspec id="font8" size="14" family="GillSans-Light" color="#000000"/>
	<fontspec id="font9" size="16" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font10" size="15" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font11" size="11" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font12" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font13" size="6" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font14" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font15" size="10" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font16" size="10" family="GillSans" color="#000000"/>
	<fontspec id="font17" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font18" size="10" family="Giovanni,Bold" color="#000000"/>
	<fontspec id="font19" size="8" family="GillSans" color="#000000"/>
	<fontspec id="font20" size="8" family="GillSans,Italic" color="#000000"/>
	<fontspec id="font21" size="8" family="GillSans,Bold" color="#000000"/>
<text top="44" left="508" width="16" height="9" font="font0" id="p1_t1" reading_order_no="1" segment_no="1" tag_type="title"><a href="http://www.biomedcentral.com/"><b>Bio</b></a></text>
<text top="44" left="525" width="22" height="9" font="font1" id="p1_t2" reading_order_no="2" segment_no="1" tag_type="title"><a href="http://www.biomedcentral.com/"><b>Med</b></a></text>
<text top="44" left="548" width="27" height="9" font="font3" id="p1_t3" reading_order_no="3" segment_no="1" tag_type="title"><a href="http://www.biomedcentral.com/">Central</a></text>
<text top="756" left="508" width="46" height="10" font="font4" id="p1_t4" reading_order_no="77" segment_no="25" tag_type="text">Page 1 of 6</text>
<text top="769" left="432" width="122" height="8" font="font5" id="p1_t5" reading_order_no="78" segment_no="26" tag_type="text"><i>(page number not for citation purposes)</i></text>
<text top="35" left="55" width="239" height="23" font="font6" id="p1_t6" reading_order_no="0" segment_no="0" tag_type="title"><b>BMC Dermatology</b></text>
<text top="86" left="502" width="79" height="10" font="font7" id="p1_t7" reading_order_no="4" segment_no="2" tag_type="title"><a href="http://www.biomedcentral.com/info/about/charter/"><b>Open Access</b></a></text>
<text top="87" left="55" width="86" height="13" font="font8" id="p1_t8" reading_order_no="5" segment_no="3" tag_type="title">Research article</text>
<text top="105" left="55" width="387" height="15" font="font9" id="p1_t9" reading_order_no="6" segment_no="4" tag_type="title"><b>Evaluation of efalizumab using safe psoriasis control</b></text>
<text top="122" left="55" width="77" height="14" font="font10" id="p1_t10" reading_order_no="7" segment_no="5" tag_type="text">Kim A Papp</text>
<text top="122" left="133" width="12" height="10" font="font11" id="p1_t11" reading_order_no="8" segment_no="5" tag_type="text">†1</text>
<text top="122" left="144" width="139" height="14" font="font10" id="p1_t12" reading_order_no="9" segment_no="5" tag_type="text"> and Eric Henninger*</text>
<text top="122" left="283" width="6" height="10" font="font11" id="p1_t13" reading_order_no="10" segment_no="5" tag_type="text">2</text>
<text top="158" left="55" width="31" height="8" font="font12" id="p1_t14" reading_order_no="11" segment_no="6" tag_type="text">Address: </text>
<text top="157" left="86" width="3" height="5" font="font13" id="p1_t15" reading_order_no="12" segment_no="6" tag_type="text">1</text>
<text top="158" left="89" width="335" height="8" font="font12" id="p1_t16" reading_order_no="13" segment_no="6" tag_type="text">Probity Medical Research, 135 Union Street East, Waterloo, Ontario, Canada, N2J 1C4, USA and </text>
<text top="157" left="424" width="3" height="5" font="font13" id="p1_t17" reading_order_no="14" segment_no="6" tag_type="text">2</text>
<text top="158" left="427" width="114" height="8" font="font12" id="p1_t18" reading_order_no="15" segment_no="6" tag_type="text">Serono International S.A., 15bis, </text>
<text top="167" left="55" width="240" height="8" font="font12" id="p1_t19" reading_order_no="16" segment_no="6" tag_type="text">chemin des Mines, Case postale 54, CH-1211 Geneva 20, Switzerland</text>
<text top="182" left="55" width="342" height="8" font="font12" id="p1_t20" reading_order_no="17" segment_no="7" tag_type="text">Email: Kim A Papp - kapapp@probitymedical.com; Eric Henninger* - eric.henninger@serono.com</text>
<text top="193" left="55" width="161" height="8" font="font12" id="p1_t21" reading_order_no="18" segment_no="8" tag_type="text">* Corresponding author    <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16984639">†Equal contributors</a></text>
<text top="341" left="112" width="44" height="10" font="font14" id="p1_t22" reading_order_no="31" segment_no="16" tag_type="title"><b>Abstract</b></text>
<text top="356" left="112" width="60" height="9" font="font15" id="p1_t23" reading_order_no="32" segment_no="17" tag_type="text"><b>Background: </b></text>
<text top="356" left="174" width="323" height="9" font="font16" id="p1_t24" reading_order_no="33" segment_no="17" tag_type="text">Safe Psoriasis Control (SPC) is an important comprehensive measure that is</text>
<text top="368" left="112" width="386" height="9" font="font16" id="p1_t25" reading_order_no="34" segment_no="17" tag_type="text">validated for the assessment of benefit:risk of psoriasis treatments, combining efficacy, quality of</text>
<text top="380" left="112" width="385" height="9" font="font16" id="p1_t26" reading_order_no="35" segment_no="17" tag_type="text">life, and safety measures. The objective of this analysis was to assess the benefit:risk of efalizumab,</text>
<text top="391" left="112" width="386" height="9" font="font16" id="p1_t27" reading_order_no="36" segment_no="17" tag_type="text">a novel biologic agent indicated for the treatment of moderate-to-severe plaque psoriasis, by</text>
<text top="403" left="112" width="362" height="9" font="font16" id="p1_t28" reading_order_no="37" segment_no="17" tag_type="text">applying the SPC to data from randomized, placebo-controlled clinical studies of efalizumab.</text>
<text top="420" left="112" width="45" height="9" font="font15" id="p1_t29" reading_order_no="38" segment_no="18" tag_type="text"><b>Methods: </b></text>
<text top="420" left="156" width="341" height="9" font="font16" id="p1_t30" reading_order_no="39" segment_no="18" tag_type="text">SPC was applied to week 12 data from four placebo-controlled, Phase III studies: three</text>
<text top="432" left="112" width="385" height="9" font="font16" id="p1_t31" reading_order_no="40" segment_no="18" tag_type="text">retrospective and one prospective, the latter including a cohort of "high-need" patients for whom</text>
<text top="443" left="112" width="193" height="9" font="font16" id="p1_t32" reading_order_no="41" segment_no="18" tag_type="text">existing therapies were inadequate or unsuitable.</text>
<text top="460" left="112" width="38" height="9" font="font15" id="p1_t33" reading_order_no="42" segment_no="19" tag_type="text"><b>Results: </b></text>
<text top="460" left="149" width="348" height="9" font="font16" id="p1_t34" reading_order_no="43" segment_no="19" tag_type="text">In the retrospective analysis, 39.4% of patients achieved SPC after 12 weeks of treatment</text>
<text top="472" left="112" width="386" height="9" font="font16" id="p1_t35" reading_order_no="44" segment_no="19" tag_type="text">with efalizumab, compared with 10.4% for placebo. In the prospective analysis, 34.3% of patients</text>
<text top="484" left="112" width="385" height="9" font="font16" id="p1_t36" reading_order_no="45" segment_no="19" tag_type="text">achieved SPC after 12 weeks of treatment with efalizumab, compared with 7.3% on placebo.</text>
<text top="495" left="112" width="321" height="9" font="font16" id="p1_t37" reading_order_no="46" segment_no="19" tag_type="text">Among high-need patients, 33.0% achieved SPC, compared with 3.4% on placebo.</text>
<text top="512" left="112" width="56" height="9" font="font15" id="p1_t38" reading_order_no="47" segment_no="20" tag_type="text"><b>Conclusion: </b></text>
<text top="512" left="169" width="328" height="9" font="font16" id="p1_t39" reading_order_no="48" segment_no="20" tag_type="text">Efalizumab has a favorable benefit:risk profile using the comprehensive outcome</text>
<text top="524" left="112" width="55" height="9" font="font16" id="p1_t40" reading_order_no="49" segment_no="20" tag_type="text">measure SPC.</text>
<text top="573" left="55" width="60" height="10" font="font14" id="p1_t41" reading_order_no="50" segment_no="21" tag_type="title"><b>Background</b></text>
<text top="585" left="55" width="241" height="9" font="font17" id="p1_t42" reading_order_no="51" segment_no="23" tag_type="text">Over the past decade, technological advancements have</text>
<text top="596" left="55" width="241" height="9" font="font17" id="p1_t43" reading_order_no="52" segment_no="23" tag_type="text">resulted in a substantial increase in the number of new</text>
<text top="608" left="55" width="241" height="9" font="font17" id="p1_t44" reading_order_no="53" segment_no="23" tag_type="text">molecules under investigation for the treatment of psoria-</text>
<text top="620" left="55" width="241" height="9" font="font17" id="p1_t45" reading_order_no="54" segment_no="23" tag_type="text">sis. At the same time has come the realization that current</text>
<text top="632" left="55" width="241" height="9" font="font17" id="p1_t46" reading_order_no="55" segment_no="23" tag_type="text">efficacy measures have significant limitations in assessing</text>
<text top="644" left="55" width="241" height="9" font="font17" id="p1_t47" reading_order_no="56" segment_no="23" tag_type="text">the full therapeutic benefit of psoriasis therapies. Despite</text>
<text top="655" left="55" width="241" height="9" font="font17" id="p1_t48" reading_order_no="57" segment_no="23" tag_type="text">its shortcomings, the most widely used measure to assess</text>
<text top="667" left="55" width="241" height="9" font="font17" id="p1_t49" reading_order_no="58" segment_no="23" tag_type="text">efficacy of new therapies has remained the Psoriasis Area</text>
<text top="679" left="55" width="241" height="9" font="font17" id="p1_t50" reading_order_no="59" segment_no="23" tag_type="text">and Severity Index (PASI) [<a href="">1,2]. Howeve</a>r, concerns</text>
<text top="691" left="55" width="241" height="9" font="font17" id="p1_t51" reading_order_no="60" segment_no="23" tag_type="text">regarding this endpoint <a href="">[3] and the lack</a> of use of PASI in</text>
<text top="702" left="55" width="241" height="9" font="font17" id="p1_t52" reading_order_no="61" segment_no="23" tag_type="text">current practice by dermatologists have resulted in the</text>
<text top="714" left="55" width="241" height="9" font="font17" id="p1_t53" reading_order_no="62" segment_no="23" tag_type="text">development of alternative measures such as the Salford</text>
<text top="726" left="55" width="241" height="9" font="font17" id="p1_t54" reading_order_no="63" segment_no="23" tag_type="text">Psoriasis Index (SPI) <a href="">[4], </a>the Self Administered PASI</text>
<text top="573" left="313" width="241" height="9" font="font17" id="p1_t55" reading_order_no="64" segment_no="22" tag_type="text">(SAPAS<a href="">I) [5],</a> the Koo-Menter Psoriasis Instrume<a href="">nt [6],</a></text>
<text top="585" left="313" width="241" height="9" font="font17" id="p1_t56" reading_order_no="65" segment_no="22" tag_type="text">and the National Psoriasis Foundation Psoriasis Score</text>
<text top="596" left="313" width="54" height="9" font="font17" id="p1_t57" reading_order_no="66" segment_no="22" tag_type="text">(NPF-P<a href="">S) [7]</a></text>
<text top="596" left="367" width="3" height="9" font="font18" id="p1_t58" reading_order_no="67" segment_no="22" tag_type="text"><b>.</b></text>
<text top="620" left="313" width="241" height="9" font="font17" id="p1_t59" reading_order_no="68" segment_no="24" tag_type="text">To more fully evaluate and interpret the benefit:risk of</text>
<text top="632" left="313" width="241" height="9" font="font17" id="p1_t60" reading_order_no="69" segment_no="24" tag_type="text">new therapies for psoriasis requires measures that assess</text>
<text top="644" left="313" width="241" height="9" font="font17" id="p1_t61" reading_order_no="70" segment_no="24" tag_type="text">multiple dimensions of the disease in a clinically mean-</text>
<text top="655" left="313" width="241" height="9" font="font17" id="p1_t62" reading_order_no="71" segment_no="24" tag_type="text">ingful way for patients and physicians alike. Safe Psoriasis</text>
<text top="667" left="313" width="241" height="9" font="font17" id="p1_t63" reading_order_no="72" segment_no="24" tag_type="text">Control (SPC<a href="">) [3</a>] is such a measure that is designed to</text>
<text top="679" left="313" width="241" height="9" font="font17" id="p1_t64" reading_order_no="73" segment_no="24" tag_type="text">improve relevance and comparability between studies</text>
<text top="691" left="313" width="241" height="9" font="font17" id="p1_t65" reading_order_no="74" segment_no="24" tag_type="text">and drugs by focusing on all clinically relevant outcomes</text>
<text top="702" left="313" width="241" height="9" font="font17" id="p1_t66" reading_order_no="75" segment_no="24" tag_type="text">so that accurate assessments can be made regarding new</text>
<text top="714" left="313" width="109" height="9" font="font17" id="p1_t67" reading_order_no="76" segment_no="24" tag_type="text">therapies for psoriasis [<a href="">8</a>].</text>
<text top="236" left="55" width="98" height="7" font="font19" id="p1_t68" reading_order_no="19" segment_no="9" tag_type="text">Published: 19 September 2006</text>
<text top="250" left="55" width="56" height="7" font="font20" id="p1_t69" reading_order_no="20" segment_no="12" tag_type="text"><i>BMC Dermatology</i></text>
<text top="250" left="111" width="22" height="7" font="font19" id="p1_t70" reading_order_no="21" segment_no="12" tag_type="text"> 2006, </text>
<text top="250" left="133" width="4" height="7" font="font21" id="p1_t71" reading_order_no="22" segment_no="12" tag_type="text"><b>6</b></text>
<text top="250" left="137" width="6" height="7" font="font19" id="p1_t72" reading_order_no="23" segment_no="12" tag_type="text">:8</text>
<text top="250" left="152" width="88" height="7" font="font19" id="p1_t73" reading_order_no="24" segment_no="12" tag_type="text">doi:10.1186/1471-5945-6-8</text>
<text top="236" left="310" width="75" height="7" font="font19" id="p1_t74" reading_order_no="29" segment_no="10" tag_type="text">Received: 11 May 2006</text>
<text top="245" left="310" width="98" height="7" font="font19" id="p1_t75" reading_order_no="30" segment_no="11" tag_type="text">Accepted: 19 September 2006</text>
<text top="264" left="55" width="244" height="7" font="font19" id="p1_t76" reading_order_no="25" segment_no="13" tag_type="text"><a href="http://www.biomedcentral.com/1471-5945/6/8">This article is available from: http://www.biomedcentral.com/1471-5945/6/8</a></text>
<text top="279" left="55" width="190" height="7" font="font19" id="p1_t77" reading_order_no="26" segment_no="14" tag_type="text">© 2006 Papp and Henninger; licensee BioMed Central Ltd.</text>
<text top="288" left="55" width="492" height="7" font="font19" id="p1_t78" reading_order_no="27" segment_no="15" tag_type="text">This is an Open Access article distributed under the terms of the Creative Commons Attribution Licens<a href="http://creativecommons.org/licenses/by/2.0">e (http://creativecommons.org/licenses/by/2.0), </a></text>
<text top="297" left="55" width="400" height="7" font="font19" id="p1_t79" reading_order_no="28" segment_no="15" tag_type="text">which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</text>
</page>
</pdf2xml>
